| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/04/2003 | US6528087 Kits for forming protein-linked lipidic microparticles |
| 03/04/2003 | US6528054 Comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a breast |
| 03/04/2003 | CA2421202A1 Endoglin-specific polypeptide, production and use thereof |
| 02/27/2003 | WO2003016917A2 Sodium channel regulators and modulators |
| 02/27/2003 | WO2003016563A2 Novel molecular target for neurotoxicity |
| 02/27/2003 | WO2003016560A2 Methods for diagnosing and treating neoplasias using nf-at transcription factors |
| 02/27/2003 | WO2003016540A2 Humanised baculovirus |
| 02/27/2003 | WO2003016532A1 Human protooncogene kg-20 and protein encoded therein |
| 02/27/2003 | WO2003016522A2 Methods and compounds for the targeting of protein to exosomes |
| 02/27/2003 | WO2003016521A2 Aav vector packaging plasmid for producing wtaav particles or pseudotyped aav particles without helper viruses, by means of a single transfection |
| 02/27/2003 | WO2003016515A2 Regulation of human glycerol-3-phosphate acyltransferase-like protein |
| 02/27/2003 | WO2003016499A2 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | WO2003016493A2 Transporters and ion channels |
| 02/27/2003 | WO2003016333A2 Virus coat protein/receptor chimeras and methods of use |
| 02/27/2003 | WO2003016328A1 Methods for the treatment and prevention of cancer |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015714A2 Compositions and therapeutic methods for viral infection |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015708A2 Composition and method for treating hiv infection |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015689A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 02/27/2003 | WO2003015613A2 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | WO2003015612A2 Materials and methods to promote repair of nerve tissue |
| 02/27/2003 | WO2003015506A1 Propagation of human hepatoblastoma cell in non-human animals |
| 02/27/2003 | WO2003000894A9 Polynucleotide vaccine |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2002099037A3 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002092134A8 Lentiviral vectors encoding clotting factors for gene therapy |
| 02/27/2003 | WO2002087472A8 Stent-based delivery of statins to prevent restenosis |
| 02/27/2003 | WO2002086091A3 Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| 02/27/2003 | WO2002081634A3 Imaging nucleic acid delivery |
| 02/27/2003 | WO2002080851A3 Chimeric vaccines |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002074794A3 Compositions useful in gene therapy |
| 02/27/2003 | WO2002072763A3 Nucleic acids, proteins, and antibodies |
| 02/27/2003 | WO2002066629A8 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 02/27/2003 | WO2002064172A3 Fhit gene therapy prevents tumor development in fhit-deficient mice |
| 02/27/2003 | WO2002061040A3 Gene delivery formulations and methods for treatment of ischemic conditions |
| 02/27/2003 | WO2002060951A3 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| 02/27/2003 | WO2002053755A3 Regulation of human otu-like cysteine protease |
| 02/27/2003 | WO2002041911A3 Use of fgf-19 for inhibiting angiogenesis |
| 02/27/2003 | WO2002030471A3 A novel system for the evaluation of the activity and/or specificity of a viral component |
| 02/27/2003 | WO2002029047A3 Regulation of human gpcr-like protein |
| 02/27/2003 | WO2002016548A8 Novel g protein-coupled receptor |
| 02/27/2003 | WO2002012290A8 Sid polypeptides binding to pathogenic strain of the hepatitis c virus |
| 02/27/2003 | WO2002009644A3 Angiogenic and osteogenic proteins for use in enhancing bone density and formation |
| 02/27/2003 | WO2002008436A3 Mini-adenoviral vector system for vaccination |
| 02/27/2003 | WO2002008267A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/27/2003 | WO2002004605A3 Stimulation of cellular regeneration and differentiation in the inner ear |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098481A3 Renal regulatory elements and methods of use thereof |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | WO2001090160A3 REGULATION OF HUMAN p78-LIKE SERINE/THREONINE KINASE |
| 02/27/2003 | WO2001075164A3 Rna sequence-specific mediators of rna interference |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030040617 For detecting, prophylaxis and therapy of disorders of the colon and/or rectum, including, but not limited to, the presence of colorectal cancer and colorectal cancer metastases |
| 02/27/2003 | US20030040505 Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| 02/27/2003 | US20030040500 Replication incompetent herpes virus vectors |
| 02/27/2003 | US20030040499 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta) |
| 02/27/2003 | US20030040498 Contacting the tumor cell with a replicon such that the replicon is taken up into tumor cell and tumor cell is killed |
| 02/27/2003 | US20030040497 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 02/27/2003 | US20030040496 Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles |
| 02/27/2003 | US20030040477 Methods and compositions for modulating t cell activation and uses thereof |
| 02/27/2003 | US20030040476 EAG gene |
| 02/27/2003 | US20030040461 Providing a cell expressing Bruton's Tyrosine Kinase; contacting cell expressing Bruton's Tyrosine Kinase with a test compound; determining whether test compound modulates the activity of Bruton's Tyrosine Kinase |
| 02/27/2003 | US20030040112 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 02/27/2003 | US20030040101 Transgenic cell for in the generation and propagation of viral expression vectors |
| 02/27/2003 | US20030040046 Netrin receptors |
| 02/27/2003 | US20030040039 Nucleotide sequences coding polypeptide for use in the treatment of diabetes |
| 02/27/2003 | US20030040007 Human BMP-7 promoter and method for exploring bone-related substance by using the same |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039994 Nucleotide sequences coding polypeptide for use in the treatment diagnosis and prevention of cancer |
| 02/27/2003 | US20030039987 Defects in periaxin associated with myelinopathies |
| 02/27/2003 | US20030039984 Sequences upstream of the CARP gene, vectors containing them and uses thereof |
| 02/27/2003 | US20030039983 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer |
| 02/27/2003 | US20030039977 Carbamate-derivatized nucleosides and oligonucleosides |
| 02/27/2003 | US20030039960 Transferring therapeutic agent into body cavity of mammal; prepare therapeutic agent, obtain mammal, inject mammal, monitor mamamlian response to therapeutic agent |
| 02/27/2003 | US20030039955 Compositions and methods for production of RNA viruses and RNA virus-based vector particles |
| 02/27/2003 | US20030039694 Periadventitial delivery device |
| 02/27/2003 | US20030039664 Isolated nucleotide sequences associated with multiple sclerosis or rheumatoid arthritis and a process of detecting |
| 02/27/2003 | US20030039660 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 02/27/2003 | US20030039657 DNA sequences encoding polypeptides of pathogens and antigens and an additional DNA sequence encoding a regulatory moiety which can bind with an administered activating agent to induce expression of an immune response |
| 02/27/2003 | US20030039647 Tetraspan protein and uses thereof |
| 02/27/2003 | US20030039646 Receptor interacting protein, which binds to itself and to other intracellular modulatory proteins; treating tumor cells or HIV-infected cells |
| 02/27/2003 | US20030039643 Investigation, diagnosis and treatment of subjects suspected of or suffering from alpha-N- acetylglucosaminidase deficiency |
| 02/27/2003 | US20030039642 Embryonic stem cells, clinical applications and methods for expanding in vitro |
| 02/27/2003 | US20030039640 Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus |
| 02/27/2003 | US20030039639 Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| 02/27/2003 | US20030039636 Novel self-inactivating (SIN) lentiviral vectors |
| 02/27/2003 | US20030039635 Compositions and methods for WT1 specific immunotherapy |
| 02/27/2003 | US20030039634 Recombinant adenoviruses, use thereof for preparing AAVS, complementary cell line, and pharmaceutical compositions containing said adenoviruses |
| 02/27/2003 | US20030039633 A replication-competent adenovirus vector comprising an adenovirus gene essential for replication; use as antitumor agent |
| 02/27/2003 | US20030039631 Adenovirus p53 compositions and methods |
| 02/27/2003 | CA2496542A1 Humanised baculovirus |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2457932A1 Sodium channel regulators and modulators |
| 02/27/2003 | CA2457823A1 Methods for diagnosing and treating neoplasias using nf-at transcription factors |